Compare Sanofi SA (SNY) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Weibo Corp — how do they compare? Sanofi SA trades at $43.94 (market cap $104.83B), while Weibo Corp trades at $8.01 (market cap $1.95B). The key difference: Sanofi SA is far larger — about 53.8× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.63%). Which is the better fit depends on your goals.
| SNY | WB | |
|---|---|---|
Market Cap | $104.83B | $1.95B |
Sector | Health | Media |
52-Week High | $52.34 | $12.83 |
52-Week Low | $41.33 | $7.20 |
Enterprise Value | $121.32B | $1.22B |
Dividend Yield | 5.5% | 7.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Weibo (WB) trades at $7.995, up 3.16% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows deep value with a P/E of 5.42 and P/B of 0.49, supported by strong profitability including a 21.15% net margin. Recent earnings have slightly missed expectations, but revenue remains stable at $1.76 billion for 2025. News highlights Weibo's cash flow generation and inclusion in value stock lists, though competitive pressures are noted.
The outlook balances significant undervaluation against competitive and execution risks. The market cap of approximately $1.8 billion is below the net balance sheet value, suggesting a margin of safety. Key risks include user engagement challenges from rivals like Douyin and reliance on advertising revenue. Analyst sentiment is mixed but leans positive, with 45% recommending Buy. The stock presents a value opportunity contingent on successful business execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
